Skip to main content

Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy

Geoffrey Porges upgraded Gilead Sciences from Market Perform to Outperform and raised the price target from $85 to $94.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.